Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases

Caeregen Therapeutics has recently received a significant boost in funding for their regenerative medicine clinical candidate, CTR-107 (Noregen™). The company was awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute. &nbsp This grant will play a crucial role in advancing the development of CTR-107, ..